Dermatology · New York, NY
NPI
1649258286
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
6
Medicare group memberships
Hospitals
0
Hospital affiliations
77 Park Ave
New York, NY, 10016
Phone (212) 826-6999
Groups this clinician bills Medicare through
Medicare paid, 2024
$391K
8,781 services
Medicare patients, 2024
993
Average age 74
Drug cost, 2024
$7.1M
15,840 prescriptions
Company payments, 2025
$2,297
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Dmitry Khasak was code 95044 (test - miscellaneous), 3,680 times for 46 patients. In total Dmitry Khasak billed 8,781 services in 50 codes, and Medicare paid $391K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-06-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95044 Test - Miscellaneous | Office | 3,680 | 46 | $4.39 | $16K |
| 99213 Office E&M - Established | Office | 2,471 | 855 | $73.63 | $182K |
| 11901 Skin | Office | 524 | 139 | $57.45 | $30K |
| 11103 Skin Biopsy | Office | 506 | 233 | $44.99 | $23K |
| 11102 Skin Biopsy | Office | 497 | 392 | $86.55 | $43K |
| 99203 Office E&M - New | Office | 295 | 294 | $87.42 | $26K |
| 17004 Destruction Skin Lesion | Office | 258 | 141 | $140.75 | $36K |
| 17003 Destruction Skin Lesion | Office | 253 | 22 | $5.99 | $1,515 |
| 10040 Removal or Shaving of Skin Growth | Office | 96 | 29 | $97.46 | $9,356 |
| 17000 Destruction Skin Lesion | Office | 32 | 30 | $50.37 | $1,612 |
| 12032 Wound Repair - All Levels | Office | 19 | 18 | $220.18 | $4,183 |
| 11404 Skin Lesion Excision | Office | 12 | 12 | $85.79 | $1,029 |
By year: 2022 $284K for 4,348 services; 2023 $405K for 8,723 services; 2024 $391K for 8,781 services.
Medicare prescription drug claims, 2024
In 2024, the drug Dmitry Khasak prescribed most often to Medicare patients was Ketoconazole, with 1,236 prescriptions and refills. In total Dmitry Khasak wrote 15,840 Medicare prescriptions that cost $7.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ketoconazole Generic | 1,236 | 1,246 | 403 | $109K |
| Ciclopirox Generic | 1,231 | 1,263 | 365 | $39K |
| Metronidazole Generic | 1,214 | 1,218 | 361 | $102K |
| Gentamicin Sulfate Generic | 871 | 889 | 535 | $32K |
| Tacrolimus Generic | 558 | 611 | 248 | $113K |
| Tavaborole Generic | 534 | 754 | 192 | $334K |
| Fluocinonide Generic | 495 | 495 | 91 | $43K |
| Pimecrolimus Generic | 468 | 518 | 193 | $123K |
| Finasteride Generic | 453 | 484 | 98 | $1,690 |
| Clobetasol Propionate Generic | 446 | 449 | 251 | $54K |
| Sulfacetamide Sodium Generic | 404 | 414 | 145 | $32K |
| Opzelura Ruxolitinib Phosphate | 399 | 402 | 132 | $787K |
| Ammonium Lactate Generic | 383 | 392 | 166 | $7,647 |
| Fluocinolone Acetonide Generic | 351 | 354 | 152 | $16K |
| Calcipotriene Generic | 324 | 343 | 116 | $109K |
Brand drugs: - claims; generic drugs: 13,451 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Dmitry Khasak $2,297 ($2,297 in general payments such as food, travel and fees) from 19 companies. The largest payer was Sun Pharmaceutical Industries Inc. with $326.
| Company | Payments | Amount |
|---|---|---|
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 8 | $326 |
| Amgen Inc. AMGN | 5 | $320 |
| Abbvie Inc. ABBV | 6 | $209 |
| Organon LLC OGN | 3 | $207 |
| Almirall LLC | 10 | $203 |
| Regeneron Healthcare Solutions, Inc. REGN | 5 | $198 |
| Genzyme Corporation SNY | 11 | $176 |
| Arcutis Biotherapeutics, Inc. ARQT | 8 | $144 |
| UCB, Inc. UCB.BR | 4 | $111 |
| Incyte Corporation INCY | 5 | $102 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.